Real World SOF/MEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAAs

Authors: David A Smith^{1,2}, Daniel Bradshaw³, Jean Mbisa³, Carmen F Manso³, David Bibby³, Josh Singer⁴, Emma Thomson⁴, Ana Filipe⁴, Elihu Aranday-Cortes⁴, M. Azim Ansari¹, Anthony Brown¹, Emma Hudson¹, Jennifer Benselin⁵, Brendan Healy⁶, Phil Troke⁷, STOP-HCV Consortium, HCV Research UK, John McLauchlan⁴, Eleanor Barnes^{1,2}, William L Irving⁵

Affiliations:

1. Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford
2. NIHR Oxford Biomedical Research Centre
3. National Infection Service, Public Health England
4. MRC-University of Glasgow Centre for Virus Research, Glasgow G61 1QH
5. NIHR Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK
6. Public Health Wales Microbiology Cardiff, University Hospital of Wales
7. Gilead Sciences Ltd., London

Corresponding Author: Daniel Bradshaw, National Infection Service, Public Health England, Colindale, 61 Colindale Avenue, London, NW9 5EQ.

Keywords: HCV; Hepatitis C Virus; Direct Acting Antivirals; DAA; Resistance Associated Substitutions; RAS; Retreatment.

Word Count: 2353 (Not including abstract, figure legends or references)

Conflicts of Interest: DB has received a research grant from Gilead. WLI has received speaker and consultancy fees from Roche, Janssen Cilag, Gilead Sciences and Novartis, educational grants from Boehringer Ingelheim, Merck Sharp and Dohme and Gilead Sciences, and research grant support from GlaxoSmithKline, Pfizer, Gilead Sciences, Janssen Cilag, Abbvie and Bristol-Myers Squibb. The remaining authors have no conflicts of interest.

Financial support statement: This work was supported by an Investigator-Sponsored Research Grant IN-UK-342-4409 "Real world assessment of retreatment of patients who have failed initial DAA therapy in the UK" from Gilead Sciences Ltd. DAS is funded by the Oxford NIHR Biomedical Research Centre. JM was funded by the UK Medical Research Council (MC_UU_12014/1). DB is funded by Public Health England. CM is funded by Public Health England. EB is/was funded by the Medical Research Council UK, the Oxford NIHR

Biomedical Research Centre and is an NIHR Senior Investigator. The views expressed in this article are those of the author and not necessarily those of the NHS, the NIHR, or the Department of Health

Author Contributions: WLI lead this work. DAS, DB and JS performed the analysis and wrote the first draft of the manuscript. This work was supervised by JMc, EB and WLI. DB, JM, CFM, JB, ET, AF, EAC, MAA, AB, EH performed viral sequencing and contributed analysis tools. WLI, JM and JB collected clinical data. DAS, DB, JM, CFM, DB, JS, ET, AF, EAC, MAA, AB, EH, JB, BH, PT, JMc, EB, WLI provided significant edits and feedback on the manuscript.

Acknowledgments: The following clinicians contributed to data collection for this project:

Clinician Name	Site Name
Dr Mathialahan	Glan Clwyd District General Hospital
Dr Rudi Matull	Taunton and Somerset NHS Foundation Trust
Professor Sumita Verma	Brighton and Sussex University Hospitals NHS Trust
	Cambridge University Hospitals NHS Foundation Trust
Dr Will Gelson	
Dr Singhal	Sandwell and West Birmingham NHS Trust
Dr Mary Ninkovic	North West Anglia NHS Foundation Trust
Dr Brendan Healy	Cardiff and Vale University Health Board
Dr Martin Prince	Manchester University NHS Foundation Trust
Dr Ahmed Elsharkawy and Professor David Mutimer	University Hospitals Birmingham NHS Foundation Trust
Dr Keith Dear	Chesterfield Royal Hospital NHS Foundation Trust
Dr Narain	Hywel Dda University Health Board
Dr Corinne Brooks	Hampshire Hospitals NHS Foundation Trust
Dr Debasish Das	Kettering General Hospital NHS Foundation Trust
Dr William Rosenberg	Royal Free London NHS Foundation Trust
Dr Sam Douthwaite	Guy's and St Thomas' NHS Foundation Trust
	Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
Dr Gavin Hill	
Dr Helen Dillon	South Warwickshire NHS Foundation Trust
Dr Jane Collier	Oxford University Hospitals NHS Foundation Trust
Dr Ivan Muscat	Jersey General Hospital
Dr Richard Aspinall	Portsmouth Hospitals NHS Trust
Dr Andrew Ustianowski	Northern Care Alliance NHS Group
	Newcastle upon Tyne Hospitals NHS Foundation Trust
Dr Stuart McPherson	
Dr Gavin Hardcastle	Aneurin Bevan University Health Board
Dr Hayley Edwards	Swansea Bay University Health Board
Dr Earl Williams and Dr Safa Al-Shamma	The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
	University Hospitals Southampton NHS Foundation Trust
Dr Mark Wright	
Dr Ivana Carey and Dr Kosh Agarwal	King's College Hospital NHS Foundation Trust

Dr Sathyanarayana and Dr Kapur	Barnsley Hospital NHS Foundation Trust
Dr Abdulkani Yusuf	Eat Sussex Healthcare NHS Trust
Dr Paul Richardson & Dr Mas Chaponda.	The Royal Liverpool and Broadgreen University Hospitals
Dr Alison Brind	University Hospitals of North Midlands NHS Trust
Dr Terry Farrant and Dr Julia Maltby	Royal United Hospitals Bath NHS Foundation Trust
	St George's University Hospitals NHS Foundation Trust
Dr Daniel Forton	Calderdale and Huddersfield NHS Foundation Trust
Dr A Verma	University Hospitals Coventry and Warwickshire NHS Trust
Dr Esther Unitt	The Leeds Teaching Hospitals NHS Trust
Dr Mark Aldersley	West Herefordshire Hospitals NHS Trust
Dr Georgina Palmes	Worcestershire Acute Hospitals NHS Trust
Dr Mark Roberts	Royal Derby Hospital
Dr Adam Lawson	Leicester Royal Infirmary
Dr Martin Wiselka	Derriford Hospital, Plymouth
Dr Matthew Cramp	Royal Hallamshire Hospital
Dr Benjamin Stone	Hull Royal Infirmary
Dr Lynsey Corless	Wycombe General Hospital
Dr David Gorard	

54

55 Abbreviations:

Sustained Viral Response	SVR
Hepatitis C Virus	HCV
Direct Acting Antiviral	DAA
Resistance Associated Substitution	RAS
Non-Structural	NS
Sofosbuvir	SOF
Ledipasvir	LDV
Velpatasvir	VEL
Glecaprevir	GLE
Pibrentasvir	PIB
European Association for the Study of the Liver	EASL
American Association for the Study of Liver Disease	AASLD
Voxilaprevir	VOX
Genotype	GT
Hepatocellular Carcinoma	HCC
Daclatasvir	DCV
Ribavirin	RBV
Public Health England	PHE
Whole Genome Sequencing	WGS
Genes Linked by Underlying Evolution	GLUE

56

Abstract

Sustained viral response (SVR) rates to first-line Direct Acting Antiviral (DAA) therapy for hepatitis C virus (HCV) infection routinely exceed 95%. However, a small number of patients require retreatment. Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is a potent DAA combination primarily used for the retreatment of patients failed by first line DAA therapies. Here we evaluate retreatment outcomes and the effects of resistance associated substitutions (RAS) in a real-world cohort, including the largest number of genotype (GT)3 infected patients, to date. 144 patients from the UK were retreated with SOF/VEL/VOX following virologic failure with first-line DAA treatment regimens. Full-length HCV genome, next-generation sequencing was performed prior to retreatment with SOF/VEL/VOX. HCV subtypes were assigned and RAS relevant to each genotype were identified (15% read cut-off). GT1a and GT3a were the two most common subtypes in the cohort, each making up 38% (GT1a n=55, GT3a n=54) of the cohort. 40% (n=58) of patients had liver cirrhosis of whom 7% (n=4) were decompensated, 10% (n=14) had hepatocellular carcinoma (HCC) and 8% (n=12) had received a liver transplant prior to retreatment. The overall re-treatment SVR12 rate was 90% (129/144). On univariate analysis, GT3 infection (50/62; SVR=81%, p=0.009), cirrhosis (47/58; SVR=81% , p=0.01) and prior treatment with SOF/VEL(12/17; SVR=71%, p=0.02) or SOF + DCV (14/19; SVR=74%, p=0.012) were all significantly associated with retreatment failure, but existence of pre retreatment RAS was not when the genotype of the virus is taken into account. The lower SVR rates achieved in patients retreated with SOF/VEL/VOX for patients with GT3 infection, cirrhosis and prior treatment with SOF/VEL or SOF/DCV has important implications for both patients and HCV elimination strategies.

81 Introduction

82 Sustained Virological Response (SVR) rates for patients chronically infected with hepatitis C
83 virus (HCV) and treated with Direct Acting Antiviral (DAA) therapies in clinical trials and real-
84 world cohorts are often >95% (1–3). Treatment failure is associated with multiple host and
85 viral factors including advanced fibrosis or cirrhosis and the presence of resistance
86 associated substitutions (RAS) in HCV-encoded proteins that are targeted by DAA (4). HCV
87 subtype is also known to have an effect on treatment outcomes; GT4r, GT3b and GT1l have
88 each shown reduced susceptibility to NS5A inhibitor-containing regimens such as sofosbuvir
89 and ledipasvir (SOF/LDV) or sofosbuvir and velpatasvir (SOF/VEL) (5–7). This means there is
90 a small percentage of HCV-infected patients who have been failed by first-line therapies and
91 are therefore by definition “difficult to treat”. Additionally, retreatment of this “difficult to
92 treat” patient population may be made more challenging, as treatment failure commonly is
93 associated with the emergence of RAS, which in the case of RAS to the NS5A inhibitor class
94 of DAAs can persist for years after treatment failure (8). For patients who have been failed
95 by pan-genotypic regimens such as SOF/VEL and glecaprevir and pibrentasvir, (GLE/PIB)
96 retreatment options are limited. Currently the European Association for the Study of the
97 Liver (EASL) and American Association for the Study of Liver Disease (AASLD), only
98 recommend a combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) for
99 these patients(9,10). However GLE/PIB + SOF is effective in small clinical trials(11) and both
100 AASLD and EASL consider it a valid alternative if patients have failed multiple rounds of
101 therapy.

102

103 Retreatment of patients previously failed by predominantly first generation NS5A inhibitor-
104 containing DAA therapy with SOF/VEL/VOX has been evaluated in both the POLARIS-1 and

POLARIS-4 phase-II and III studies (12), with SVR rates in excess of 95%. In these trials most patients retreated with SOF/VEL/VOX (228/445; 51%) and (132/445; 29%) were infected with HCV GT1 and GT3 respectively, 46% of the patients had cirrhosis and 49-83% had detectable RAS before retreatment. Nevertheless, SOF/VEL/VOX showed a very high SVR rate in GT1 infected patients (222/228; 97% SVR); however, a slightly higher virologic failure rate in GT3 patients was observed (126/132; 95% SVR). A number of studies have evaluated the observed real-world outcomes of SOF/VEL/VOX retreatment, in both the US and Europe. The largest cohort (n=573) from the US, reported by Belperio, et al (13), showed lower SVR rates than in the POLARIS 1 and 4 studies for all genotypes (GT1: 429/473; 91% SVR, GT2: 18/20; 90% SVR, GT3: 42/46; 91% SVR, GT4: 12/12; 100% SVR). This study also showed that the SVR rate for those who had received SOF/VEL as a first-line therapy, was reduced for GTs 1-3 (GT1: 15/19; 79% SVR, GT2: 13/15; 87% SVR, GT3: 11/13; 85% SVR). In an Italian cohort (14), the SVR rate was 95% (162/169) with cirrhosis and hepatocellular carcinoma (HCC) being associated with treatment failure, however there was no significant difference between the SVR rates of patients with different genotypes (GT1: 98/101; 97% SVR, GT2: 17/17; 100% SVR, GT3: 33/36; 91% SVR, GT4: 14/15; 93% SVR). Finally, Llaneras, et al (15) reported an overall SVR rate of 95% (128/135) with 100% in patients with GT1 (82/82) and GT2 (7/7) infection, 80% (24/30) in GT3 and 93% (13/14) in GT4. SVR rates were significantly lower in patients with cirrhosis (89%, $p = 0.05$), or those with GT3 infection (80%, $p < 0.001$), whilst patients with GT3 infection and cirrhosis had the lowest SVR rate (69%).

Despite these studies there remains limited data from the real-world setting, particularly in patients with GT3 infection and on the prevalence of post-treatment RAS amongst patients not achieving SVR with first line DAA treatment and the potential impact of these RAS on

SOF/VEL/VOX retreatment outcomes. Data following unsuccessful therapy with pan-genotypic DAA regimens such as SOF/VEL or GLE/PIB retreated with SOF/VEL/VOX is particularly lacking and these data are urgently required to inform optimal retreatment strategies. In this paper we report the outcomes of 144 patients failed by first line DAA therapy and retreated with SOF/VEL/VOX. We then analyse the effect of clinical characteristics and RAS on SOF/VEL/VOX retreatment.

Results

Baseline characteristics of patients

Outcomes were available for 144 patients who were retreated with SOF/VEL/VOX. The mean age was 56 years (49-63 IQR) with 84% (n=121) of the cohort being male. Overall, 40% (n=58) had cirrhosis, with 7% (n=4) decompensated. 10% (n=14) had HCC and 8% (n=12) had received a liver transplant prior to retreatment (Table 1). GT1a and GT3a were the two most common subtypes, each making up 38% (GT1a n=55, GT3a n=54) of the cohort, 17 other subtypes were identified from genotypes 1,2,3,4 and 6, with GT1b, GT4r and GT3b making up 6% (n=9), 4% (n=6), and 3% (n=5) of the cohort respectively (Figure 1).

Effectiveness of retreatment with SOF/VEL/VOX

The overall SVR12 rate for patients retreated with SOF/VEL/VOX was 91% (Figure 2). The majority of patients who did not achieve an SVR (n=15) experienced a post treatment relapse (n=10). One patient experienced an on-treatment breakthrough (patient's HCV RNA is undetectable during treatment and then becomes detectable again during treatment.) and two were non-responders (patients who never achieve

undetectable HCV RNA). Relapse/breakthrough/non-response was not reported by the treating clinician for the remaining two patients.

Evaluating the factors associated with outcome using univariable logistic regression, GT3 infection (52/64; SVR=81%, $p=0.009$) and cirrhosis (47/58; SVR=81%, $p=0.01$) were both significantly associated with treatment outcome (Figure 3). Patients whose initial regimen was either SOF/VEL or SOF + DAC were also less likely to achieve SVR on retreatment (12/17, 71% $p=0.02$ and 14/19, 74%, $p=0.012$ respectively). Patients with GT3 infection, cirrhosis and prior treatment with SOF/VEL had the lowest SVR rate of 42% (3/7). However, one of these patients only received 4 weeks of SOF/VEL/VOX (Supplementary Table 2). Multivariable analysis using logistic regression with SVR as the response variable and GT, presence/absence of cirrhosis and previous treatment regimen included as explanatory variables, revealed that prior treatment with SOF/VEL had the largest effect on SVR and remained the only variable significantly associated with outcome ($p=0.03$) (Supplementary Figure 1). However, with the exception of one GT1 patient previously treated with SOF/VEL, all patients with prior SOF/VEL or SOF + DCV treatment had GT3 infection which confounded this result (Table 1). When GT3-infected patients were analysed separately, cirrhosis and prior treatment regimen were no longer significantly associated with outcome, in both the univariable and multivariable analysis.

Effect of resistance-associated substitutions on retreatment outcome

Among the 144 patients retreated with SOF/VEL/VOX and with available outcomes, 70% (101/144) had detectable RAS prior to retreatment. 16% had NS3 inhibitor RAS, 51% NS5A

inhibitor RAS and 34% SOF RAS. Of the viral sequences in 15 patients failed by SOF/VEL/VOX retreatment, 12/15 (80%) had detectable RAS prior to retreatment compared to 89/129 (68%) in those subsequently achieving SVR. However, despite the high prevalence of RAS, the presence of a RAS in a particular protein or combination of proteins was not significantly associated with outcome (Table 2). When each RAS was considered independently using logistic regression, A30K and Y93H RAS in NS5A were associated with retreatment failure in the whole cohort (A30K $p=0.02$, Y93H $p=0.01$) (Table 3). The A30K RAS is unique to GT3a (it is wild-type in GT3b) and the Y93H substitution was much more common in GT3 patients compared to other genotypes (Supplementary Figure 2). When the analysis is limited to GT3 patients, the SVR rates for patients with these RAS were still reduced (for A30K SVR, 71% and Y93H SVR, 78%) but this was no longer statistically significant (A30K $p=0.2$, Y93H $p=0.3$). In addition, when genotype is added as a cofactor to the logistic regression Y93H is no longer associated with outcome. Whilst individually the A30K and Y93H RAS are common, the combination of A30K + Y93H is found rarely and is not associated with treatment outcome in this cohort (Supplementary Figure 3). No other RAS was significantly associated with outcome within the whole cohort or within a specific genotype of patients.

Discussion

This cohort represents both the largest reported cohort of patients retreated with SOF/VEL/VOX in the UK, and the largest cohort of GT3-infected patients retreated with SOF/VEL/VOX. Our results show that retreatment of patients with SOF/VEL/VOX who have been failed by first-line therapy is very effective for GT1. However, patients with GT3 infection, cirrhosis or prior treatment with SOF/VEL or SOF/DCV have significantly lower SVR rates with SOF/VEL/VOX retreatment.

Our data shows that GT3-infected patients achieved lower SVR rates to SOF/VEL/VOX retreatment; the lowest SVR12 rates (42%) were observed in patients with GT3 infection, cirrhosis and prior SOF/VEL exposure. This is consistent with the data from Llaneras et al (15), which also showed a SVR rate of 81% for GT3-infected patients and 69% for GT3-infected patients with cirrhosis. Belperio, et al (13) have shown that GT1-infected patients with prior SOF/VEL exposure had a reduced SVR rate of 79% (15/19), yet a GT3-infected group with prior SOF/VEL exposure had a SVR rate of 85% (11/13) which is greater than the 75%(12/16) that was observed in the GT3-infected patients in our study but, these numbers remain small.

The overall prevalence of RAS was very high in this cohort and the presence of the NS5A inhibitor RAS Y93H was significantly associated with treatment failure across the whole cohort. However, when genotype is included in the model used to test association, Y93H is no longer significantly associated with outcome. This data suggests that viral genotype is the more important viral factor for SOF/VEL/VOX retreatment outcome than the presence of RAS. However, PIB has been shown to be more effective than other NS5A inhibitors against viruses harbouring the Y93H RAS in-vitro (16). This could mean that GLE/PIB would be more effective against virus strains harbouring the Y93H RAS. Thus, RAS testing to guide retreatment therapy could be an effective way to increase retreatment SVR rates.

At present SOF/VEL/VOX is the only recommended retreatment regimen for patients previously failed by a NS5A inhibitor containing regimen in England. These data suggest that whilst SOF/VEL/VOX may be a preferred regimen for non-GT3 infected patients, an

alternative retreatment regimen for GT3-infected patients should also be considered, particularly those with cirrhosis and previous exposure to a DAA regimen containing VEL or DCV. One current alternative to SOF/VEL/VOX for these patients is the off-label use of GLE/PIB + SOF +/-RBV. This combination was effective in a small retreatment trial (11) and could represent an effective retreatment option for GT3 patients with prior exposure to SOF/VEL. Further options include adopting a resistance guided approach to treatment, increasing the SOF/VEL/VOX treatment duration or adding ribavirin.

In summary, our study shows that retreatment outcomes for patients failed by first-line DAA therapy is very successful for non-GT3-infected patients. However, for GT3-infected patients, particularly those with cirrhosis and failed by initial SOF/VEL treatment, SVR rates were significantly lower and alternative retreatment regimens such as GLE/PIB + SOF should be considered.

Methods

Patients and Samples

This study included 215 individuals from across England, United Kingdom who did not achieve a SVR with previous interferon-free DAA treatment. Blood samples were taken prior to retreatment and samples sent to Oxford and Glasgow for HCV whole genome sequencing (WGS). Clinical, demographic and treatment outcome data were collected from patients, who were enrolled in HCV Research UK (n=37), following informed consent and ethical approval (17). For patients not enrolled in HCV Research UK, whole genome HCV sequences

and anonymised clinical data were provided by Public Health England (PHE), collected as part of the Virus Reference Department's 's HCV antiviral resistance testing service. This provides a clinical service for National Health Service Trusts, which send patients' blood samples for HCV genotyping and resistance testing by WGS and receive results in real time to inform clinical management. Approval for the use of data from this service was granted under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002. For retreatment, SVR was defined a minimum of 12 weeks after the end of treatment.

Whole Genome Sequencing of HCV

Whole HCV genome sequencing was conducted at three sites to define HCV subtype and identify RAS: (i) The MRC-University of Glasgow Centre for Virus Research (CVR), (ii) The Peter Medawar Building for Pathogen Research, University of Oxford, and (iii) The Virus Reference Department, National Infection Service, Public Health England. These sites have previously collaborated to ensure uniform standards for HCV sequencing (18). Briefly, RNA was isolated from patient plasma samples and reverse transcribed to produce cDNA. An Illumina sequencing library was generated and enriched for HCV viral sequences using specific oligonucleotide probes. Illumina sequencing reads were then processed and mapped to the closest HCV reference genome. Precise details of how the sequencing was performed at each site is described in the supplementary materials.

Resistance Associated Substitution Calling using HCV-GLUE

HCV subtypes were assigned and NS3, NS5A and NS5B RAS relevant to each genotype were identified (15% of reads cut off) using HCV-GLUE and RAS definitions provided by PHE (19) (Supplementary Table 3). HCV-GLUE is a resource created as part of the STOP-HCV

consortium based on the GLUE (Genes Linked by Underlying Evolution) platform (20). HCV-GLUE uses the ICCT HCV reference sequences and collates publicly available HCV sequences, to construct phylogenies using RAxML to assign sequences to HCV clades. It also contains a database of HCV RAS created by PHE (19) and this is used to identify RAS relevant to the HCV genotype and subtype (21).

Statistical Analysis

All statistical analysis was performed using custom code and R version 3.6.2. Logistic regression was used for analysis of association between categorical variables.

References

1. **Wei L, Lim SG**, Xie Q, Văn KN, Piratvisuth T, Huang Y, et al. Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. *Lancet Gastroenterol. Hepatol.* 2019;
2. Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, et al. Sofosbuvir with velpatasvir in treatment-naïve noncirrhotic patients with genotype 1 to 6 hepatitis c virus infection. *Ann. Intern. Med.* 2015;163.
3. Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, et al. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. *J. Hepatol.* [Internet]. 2018;68:895–903. Available from: <https://doi.org/10.1016/j.jhep.2017.11.032>
4. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype

- 287 3 infection: ALLY-3 phase III study. Hepatology [Internet]. 2015 [cited 2017 Sep
288 11];61:1127–35. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25614962>
- 289 5. da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, et al.
290 Response to DAA therapy in the NHS England Early Access Programme for rare HCV
291 subtypes from low and middle income countries. J. Hepatol. [Internet]. 2017 [cited
292 2017 Aug 24];67:1348–1350. Available from:
293 <http://www.ncbi.nlm.nih.gov/pubmed/28789880>
- 294 6. **Smith D, Magri A**, Bonsall D, Ip CL, Trebes A, Brown A, et al. Resistance analysis of
295 genotype 3 HCV indicates subtypes inherently resistant to NS5A inhibitors.
296 Hepatology [Internet]. 2018 [cited 2018 Apr 20];00:1–12. Available from:
297 <http://doi.wiley.com/10.1002/hep.29837>
- 298 7. Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, et al. Frequent antiviral
299 treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r.
300 Hepatology [Internet]. 2018; Available from: <http://doi.wiley.com/10.1002/hep.30225>
- 301 8. Yoshimi S. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in
302 patients who failed daclatasvir and asunaprevir therapy. J. Med. Virol. 2015;
- 303 9. Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL
304 Recommendations on Treatment of Hepatitis C 2018. J. Hepatol. [Internet].
305 2018;69:461–511. Available from: <https://doi.org/10.1016/j.jhep.2018.03.026>
- 306 10. American Association for the Study of Liver Diseases. Recommendations for Testing,
307 Managing, and Treating Hepatitis C | HCV Guidance [Internet]. [cited 2017 Dec
308 8]; Available from: <http://www.hcvguidelines.org/>
- 309 11. Wyles D, Weiland O, Yao B, Weilert F, Dufour J-FF, Gordon SC, et al. Retreatment of
310 patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.

- 311 J. Hepatol. [Internet]. 2019 [cited 2019 Mar 18];70:1019–1023. Available from:
312 <https://www.sciencedirect.com/science/article/pii/S0168827819300789?via%3Dihub>
- 313 12. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir,
314 Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N. Engl. J. Med.
315 [Internet]. 2017 [cited 2017 Dec 11];376:2134–2146. Available from:
316 <http://www.nejm.org/doi/10.1056/NEJMoa1613512>
- 317 13. Belperio PS, Shahoumian TA, Loomis TP, Backus LI. Real-world effectiveness of
318 sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis
319 C patients. J. Viral Hepat. 2019;
- 320 14. Degasperis E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, et al. Real-life
321 effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients
322 with previous daa failure. J. Hepatol. 2019;71:1106–1115.
- 323 15. Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, García-Samaniego J, et al.
324 Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with
325 chronic hepatitis C previously treated with DAAs. J. Hepatol. 2019;71:666–672.
- 326 16. Gottwein JM, Pham L V., Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, et al.
327 Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1–7 and Escape
328 Variants. Gastroenterology [Internet]. 2017;154:1435–1448. Available from:
329 <http://linkinghub.elsevier.com/retrieve/pii/S0016508517367203>
- 330 17. McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, et al. Cohort
331 Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. Int. J.
332 Epidemiol. 2017;46.
- 333 18. Thomson E, Ip CLC, Badhan A, Christiansen MT, Adamson W, Ansari MA, et al.
334 Comparison of Next-Generation Sequencing Technologies for Comprehensive

335 Assessment of Full-Length Hepatitis C Viral Genomes. J. Clin. Microbiol. [Internet].
336 2016 [cited 2016 Nov 8];54:2470–2484. Available from:
337 <http://jcm.asm.org/lookup/doi/10.1128/JCM.00330-16>

338 19. Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, et al. Consensus
339 recommendations for resistance testing in the management of chronic hepatitis C
340 virus infection: Public Health England HCV Resistance Group. J. Infect. 2019;79:503–
341 512.

342 20. Singer JB, Thomson EC, McLauchlan J, Hughes J, Gifford RJ. GLUE: A flexible software
343 system for virus sequence data. BMC Bioinformatics. 2018;19.

344 21. Singer J, Thomson E, Hughes J, Aranday-Cortes E, McLauchlan J, da Silva Filipe A, et al.
345 Interpreting Viral Deep Sequencing Data with GLUE. Viruses [Internet]. 2019;11:323.
346 Available from: <https://www.mdpi.com/1999-4915/11/4/323>
347
348

349 Tables

	GT1 (n=66)	GT2 (n=3)	GT3 (n=62)	GT4 (n=10)	GT6 (n=3)
Demographics					
Median Age (IQR), years	54 (48-60)	64 (56-67)	57 (51-62)	62 (57-75)	27 (27-44)
Sex: Male	86% (56/65)*	67% (2/3)	85% (53/62)	70% (7/10)	100% (3/3)
Liver Disease State					
Cirrhosis	24% (16/66)	67% (2/3)	60% (37/62)	30% (3/10)	0% (0/3)
Decompensated Cirrhosis	0% (0/16)	0% (0/2)	11% (4/37)	0% (0/3)	0% (0/0)
Hepatocellular Carcinoma	9% (6/66)	0% (0/3)	13% (8/62)	0% (0/10)	0% (0/3)
Prior Liver Transplant	3% (2/66)	33% (1/3)	15% (9/62)	0% (0/10)	0% (0/3)
Mean Baseline Viral Load, log₁₀ IU/mL (IQR)	6.6 (6.0-6.7)	6.0 (5.9-6.2)	6.4 (5.5-6.5)	7.1 (5.6-6.7)	6.2 (6.0-6.3)
Previous DAA Treatment Regimen**					
SOF/LDV	38% (25/66)	-	10% (6/62)	40% (4/10)	-
SOF/VEL	2% (1/66)	-	26% (16/62)	-	-
GLE/PIB	2% (1/66)	-	24% (15/62)	-	100% (3/3)
SOF + DCV	-	-	31% (19/62)	-	-
EBR/GZR	15% (10/66)	-	-	20% (2/10)	-
OBV/PTVr +/- DAS	32% (21/66)	-	2% (1/62)	30% (3/10)	-
SOF	2% (1/66)	100% (3/3)	6% (4/62)	-	-
Unknown	11% (7/66)	-	2% (1/62)	10% (1/10)	-

Table 1: Clinical characteristics of 144 patients prior to retreatment with SOF/VEL/VOX split by genotype. Daclatasvir (DCV), Sofosbuvir (SOF), Glecaprevir (GLE), Pibrentasvir (PIB), Grazoprevir (GZR), Elbasvir (EBR), Ledipasvir (LDV), Paritaprevir (PTV), Ombitasvir (OBV) Ritonavir (r), Dasabuvir (DAS), Velpatasvir (VEL). *Data missing for one patient. **Full breakdown of previous treatment regimens including ribavirin and interferon use are in Supplementary Table 1

Presence of RAS	Prevalence % (n)	SVR Rate % (n)	p	log Odds Ratio	Standard Error
No RAS	30% (43/144)	93% (40/43)	NA	NA	NA
NS3	16% (23/144)	100% (23/23)	0.9	15.9	2062
NS5A	51% (74/144)	86% (64/74)	0.3	-0.7	0.8
NS5B	34% (49/144)	84% (41/49)	0.5	-0.5	0.96
NS3 + NS5A	8% (12/144)	100% (12/12)	0.9	15.9	1882
NS3 + NS5B	0% (0/144)	NA	NA	NA	NA
NS5A + NS5B	22% (31/144)	80% (25/31)	0.1	-1.1	0.75
NS3 + NS5A + NS5B	1% (1/144)	100% (1/1)	0.9	15.9	6522

Table 2: Prevalence of pre-retreatment RAS and SVR rates for patients retreated with SOF/VEL/VOX. Logistic regression was used to test the association between presence of RAS in the NS3, NS5A and NS5B proteins with SVR.

362

	RAS	SVR Rate % (n)	p	log Odds Ratio	Standard Error
Protein					
NS3	V55A	100 (4/4)	0.99	14.446	1199.772
	K/Q80K	100 (14/14)	0.992	16.331	1638.472
	K/Q80L	100 (2/2)	0.993	14.43	1696.734
	Q80R	100 (1/1)	0.993	13.422	1455.398
	A156T	100 (1/1)	0.993	13.422	1455.398
	L175M	100 (1/1)	0.993	13.422	1455.398
NS5A	M28T	100 (5/5)	0.993	15.454	1769.258
	A30K	71 (10/14)	0.029	-1.465	0.67
	K/R30K	100 (1/1)	0.993	13.422	1455.398
	L/M31M	100 (2/2)	0.993	14.43	1696.734
	L31M	100 (16/16)	0.992	16.373	1543.764
	L31V	100 (3/3)	0.992	14.438	1385.378
	H58D	100 (9/9)	0.99	15.183	1201.731
	Y93C	100 (4/4)	0.99	14.446	1199.772
	Y93H	78 (29/37)	0.014	-1.371	0.559
	Y93N	100 (2/2)	0.993	14.43	1696.734
NS5B	A/T/V150V	93 (26/28)	0.531	0.495	0.791
	F/L159F	67 (2/3)	0.229	-1.512	1.257
	L159F	100 (2/2)	0.993	14.43	1696.734
	E/K206E	80 (16/20)	0.142	-0.943	0.642
	E237G	100 (1/1)	0.993	13.422	1455.398
	D/N244I	100 (1/1)	0.993	13.422	1455.398
	C/N316H	100 (1/1)	0.993	13.422	1455.398
	C/N316N	75 (3/4)	0.355	-1.099	1.189
	I/V321I	50 (1/2)	0.125	-2.213	1.442
	V321I	100 (1/1)	0.993	13.422	1455.398

363 **Table 3: SVR rates for patients retreated with SOF/VEL/VOX with individual pre**
364 **retreatment RAS.** Logistic regression was used to test the association between presence of
365 RAS with outcome in the whole cohort.

366